Browsing Molecular Pathology by author "Wilding, Christopher"
Now showing items 1-9 of 9
-
Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?
Cojocaru, E; Wilding, C; Engelman, B; Huang, P; Jones, RL (Springer Science and Business Media LLC, 2020-03-01)<jats:title>Abstract</jats:title><jats:p>Chondrosarcomas are rare cancers of bone that arise from the malignant transformation of cells of chondrocytic lineage. They are known to be resistant to systemic cytotoxic chemotherapy ... -
Mapping the dynamic immune landscape associated with therapeutic response in soft tissue sarcoma
Huang P; Wilding, C; Huang, P (Institute of Cancer Research (University Of London), 2023-10-24)Soft tissue sarcomas (STS) are a group of rare and heterogenous cancers of unmet need. In the advanced setting, and following failure of first-line anthracycline therapy, further line therapeutic options offer limited ... -
Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
Chamberlain, FE; Wilding, C; Jones, RL; Huang, P (TAYLOR & FRANCIS LTD, 2019-07-03)Introduction: Liposarcomas (LPS) are a heterogeneous group of adipocytic soft tissue sarcomas with limited treatment options in the advanced/metastatic setting. Pazopanib is a multi-target tyrosine kinase inhibitor (TKI) ... -
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry.
Milighetti, M; Krasny, L; Lee, ATJ; Morani, G; Szecsei, C; et al. (ELSEVIER, 2021-06-15)Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers. While large-scale genomic and epigenomic profiling of STS have been undertaken, proteomic analysis has thus far been limited. Here we utilise ... -
Proteomic research in sarcomas - current status and future opportunities.
Burns, J; Wilding, CP; L Jones, R; H Huang, P (ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2020-04-01)Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains ... -
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
Pacini, L; Jenks, AD; Vyse, S; Wilding, CP; Arthur, A; et al. (DOVE MEDICAL PRESS LTD, 2021-03-08)Insertion mutations in exon 20 (Ex20ins) of the epidermal growth factor receptor (EGFR) gene are the largest class of EGFR mutations in non-small cell lung cancer (NSCLC) for which there are currently no approved targeted ... -
The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma.
Lee, ATJ; Chew, W; Wilding, CP; Guljar, N; Smith, MJ; et al. (NATURE PORTFOLIO, 2019-10-10)The characterisation and clinical relevance of tumour-infiltrating lymphocytes (TILs) in leiomyosarcoma (LMS), a subtype of soft tissue sarcoma that exhibits histological heterogeneity, is not established. The use of tissue ... -
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
Wilding, CP; Elms, ML; Judson, I; Tan, A-C; Jones, RL; et al. (TAYLOR & FRANCIS LTD, 2019-10-30)Introduction: Tyrosine kinases are key mediators of intracellular signaling cascades and aberrations in these proteins have been implicated in driving oncogenesis through the dysregulation of fundamental cellular processes ... -
Tropomyosin receptor kinase inhibitors in the management of sarcomas.
Wilding, CP; Loong, HH; Huang, PH; Jones, RL (LIPPINCOTT WILLIAMS & WILKINS, 2020-06-05)PURPOSE OF REVIEW: Genetic aberrations resulting in tropomyosin receptor kinase (TRK) fusion proteins can drive oncogenesis and are postulated to occur in up to 1% of solid tumours. However, TRK fusions in adult sarcomas ...